Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 712737 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Search Results

Your Search for 'Angiogenesis Inhibitors - State-of-the-Science and Strategic Opportunities' returned 73 results - Page 1 of 4

  Sort by   
  Sorted by Rank Top-Bottom

Angiogenesis Inhibitors and Stimulators - Global Strategic Business Report  
Global Industry Analysts, Inc., Feb 2011, Pages: 682
and custom watermarks. For information on site licence pricing please click on Enquire before buying ANGIOGENESIS INHIBITORS AND STIMULATORS A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS 1


Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others  
Bioseeker, Jan 2012, Pages: 1704
This report will excel your competitive awareness and decrease your decision making time in managing angiogenesis affecting drug development in cancer. Find out whether you are number one, two


Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline  
Bioseeker, Sep 2010, Pages: 1227
This report comprises defined and up to date development strategies for 239 angiogenesis affecting drugs in oncology within the portfolio of 148 corporate investigators, from Ceased to Marketed


Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, Jan 2012, Pages: 4763
This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Apoptosis, Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts


Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides  
Bioseeker, Jan 2012, Pages: 4052
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Peptides


Triple Analysis: Breast Cancer, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, Jan 2012, Pages: 4059
This triple analysis focuses on cancer drug development strategies in Breast Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three


Triple Analysis: Colorectal Cancer, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, Jan 2012, Pages: 4202
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each


Triple Analysis: Leukemia, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, Jan 2012, Pages: 4293
This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three


Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, Jan 2012, Pages: 4469
This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three


Triple Analysis: Lymphoma, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, Jan 2012, Pages: 4100
This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three


Triple Analysis: Melanoma, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, Jan 2012, Pages: 3923
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three


Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, Jan 2012, Pages: 3756
This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each


Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, Jan 2012, Pages: 3984
This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three


Triple Analysis: Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors  
Bioseeker, Jan 2012, Pages: 3805
This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors. Each of these three individual parts


Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies  
Bioseeker, Jan 2012, Pages: 5090
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Antibodies


Challenges and Opportunities in Developing Chemopreventive Agents  
Decision Resources, Inc., Nov 2007, Pages: 29
Agents EGFR Inhibitors HMG-CoA Reductase Inhibitors Angiogenesis Inhibitors Matrix Metalloproteinases Combination Therapies Strategic Alliances with Nutraceutical Companies Biomarker Development


Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth  
Datamonitor, April 2010, Pages: 243
with greater efficacy Small molecules Small molecules targeting tyrosine kinases have been a significant development in oncology drug discovery Classification of pipeline products Angiogenesis inhibitor


Histone Deacetylase inhibitors  
Lead Discovery, May 2005
inhibitors has been driven by their ability to modulate transcriptional activity. As a result, this therapeutic class is able to block angiogenesis and cell cycling, and promote apoptosis and differentiation


U.S. Emerging Cancer Therapeutics Markets  
Frost & Sullivan, Jan 1999
.S. Market for Angiogenesis Inhibitors - Strategic Analysis and Forecasts of the Total Market - Competitive Structure - Research and Development Pipeline - The Role of Market Engineering in the Pharmaceutical


The Complete Guide to Targeted Therapies in Oncology: A World Review  
Bioseeker, Dec 2006, Pages: 550
.2.3 Integrins in Angiogenesis 10.2.4 Inhibitors of Angiogenesis 10.3 Vascular Targeting Agents 10.4 Vascular Disruptive Agents 10.5 Competitive Landscape in Anti-Angiogenesis and Vascular Targeting in Oncology


Results:  First -   Prev -   1 -   2 -   3 -   4 -   Next -   Last


For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds